ArticleJAMA network open2026
Residential Radon Levels and Ovarian Cancer Among Postmenopausal Women.
Article in JAMA network open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
Importance: Few environmental risk factors for ovarian cancer have been discovered. Women exposed to ionizing radiation from the atomic bomb during World War II experienced an increased risk of ovarian cancer. Today, the largest source of ionizing radiation is radon gas in the home, but whether ionizing radiation is associated with increased risk of ovarian cancer more broadly is unknown. Objective: To evaluate whether higher home radon levels are associated with increased risk of ovarian cancer. Design, Setting, and Participants: This prospective cohort study included 127 547 women from the Women's Health Initiative, including 40 clinical centers across the US, with outcomes followed up for 31 years (1993-2024). Postmenopausal women aged 50 to 79 years were enrolled in an observational study or 1 or more randomized clinical trials. All cases of ovarian cancer were physician adjudicated. Exposure: Radon measurements from the 1993 US Geological Survey, classified into low (<2 pCi/L), medium (2-4 pCi/L), and high zones (>4 pCi/L), were linked with the geocoded home addresses of participants at baseline (1993-1998). Main Outcomes and Measures: Hazard ratios (HRs) for ovarian cancer, adjusted for covariates with 95% CIs. Results: Among the 127 547 women (mean [SD] age, 63.1 [7.2] years) with available radon zone values, 1645 incident ovarian cancers and 1048 ovarian cancer deaths were observed over a mean (SD) follow-up of 17.7 (8.4) years. After adjustment for covariates, the HR for all ovarian cancers for women living in the medium radon zone compared with women living in the low radon zone was not significantly higher (HR, 1.13 [95% CI, 1.00-1.29]). However, the HR was significantly higher for women living in the high radon zone compared with those living in the low radon zone (HR, 1.31 [95% CI, 1.11-1.54]). Similar findings were observed for the most common histologic type, serous ovarian cancer, for which the HR in the medium zone was 1.06 (95% CI, 0.88-1.27) and the HR in the high zone was 1.38 (95% CI, 1.09-1.74). Ovarian cancer mortality also was significantly higher in the high radon zone compared with the low radon zone (HR, 1.31 [95% CI, 1.07-1.60]). Sensitivity analyses using 3 alternate radon measures produced similar results. Conclusions and Relevance: In this large, prospective cohort of postmenopausal women, the risks of ovarian cancer incidence and mortality were significantly higher for women living in homes in the high radon zone. Residential radon is a ubiquitous and modifiable risk factor. This is the first epidemiologic study of radon and ovarian cancer among postmenopausal women to date, and its findings suggest a potential target for mitigating cancer risk.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.